Epizyme Announces Third Quarter 2015 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. LVS
9. QGEN
10. SPY

Go back to Epizyme Announces Third Quarter 2015 Financial Results and Provides Corporate Update

RBC Affirms Epizyme (EPZM) at 'Outperform' as Ttazemetostat Enrollment Continues

November 9, 2015 12:43 PM EST

RBC Captial affirms Epizyme (Nasdaq: EPZM) at Outperform with a price target of $39 following Q3 results and update issued earlier.

Analyst Simos Simeonidis noted the following:

Enrollment continues in 150-patient Phase II study in NHL in Europe: On their 3Q15 earnings call this morning, management stated that plans remain on track for tazemetostat's Phase II programs. Patients are currently being enrolled in the 5-arm,... More

Epizyme (EPZM) Tops Q3 EPS by 3c

November 9, 2015 6:30 AM EST

Epizyme (NASDAQ: EPZM) reported Q3 EPS of ($0.56), $0.03 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $358 thousand versus the consensus estimate of $5.42 million.

For earnings history and earnings-related data on Epizyme (EPZM) click here.

... More